Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 8:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 260 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Streptococcus pneumoniae vaccine Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

NCT05412030
View directory record Official record
Conditions
Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions
AFX3772, Prevnar 13, Prevnar 20
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
42 Days to 90 Days
Enrollment
388 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
42
States / cities
Jonesboro, Arkansas • Los Angeles, California • Miami, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 5, 2026, 8:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age

NCT05489328
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
Candidate-1, Candidate-2, Candidate-3, Candidate-4, Candidate-5, Candidate-6, Candidate Control, 13vPnC, PCV15
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
394 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
18
States / cities
Tustin, California • Walnut Creek, California • Milford, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 5, 2026, 8:51 AM EDT
Completed No phase listed Observational Results available

Impact of Prevnar 13 on Ear Infections in Children

NCT01272999
View directory record Official record
Conditions
Acute Otitis Media, Mastoiditis
Interventions
No intervention
Other
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 5, 2026, 8:51 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

NCT01681992
View directory record Official record
Conditions
Measles, Mumps, Rubella, Measles-Mumps-Rubella Vaccine
Interventions
Priorix, M-M-R II, Varivax, Havrix, Prevnar 13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
4,538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 5, 2026, 8:51 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated

NCT01025336
View directory record Official record
Conditions
Healthy
Interventions
Blood draw
Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years and older
Enrollment
962 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
29
States / cities
Chandler, Arizona • Phoenix, Arizona • Denver, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 5, 2026, 8:51 AM EDT
Completed No phase listed Observational Results available

Effect of Prevnar 13 on Ear Infections in Children

NCT01199016
View directory record Official record
Conditions
Otitis Media
Interventions
Tympanocentesis, Nose/throat swab, Observational
Procedure · Biological
Lead sponsor
Pfizer
Industry
Eligibility
6 Months to 30 Months
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
7
States / cities
Penfield, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 5, 2026, 8:51 AM EDT
Completed No phase listed Observational Results available

FeverText: Assessing Fever Rates After Vaccination During the 2011-12 Influenza Season Using Text Messaging

NCT01467934
View directory record Official record
Conditions
Fever
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
6 Months to 23 Months
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 5, 2026, 8:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase I Safety Trial of Streptococcus Pneumoniae Whole Cell Vaccine (SPWCV) + Alum in Healthy Adults

NCT01537185
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
Placebo, SPWCV+Alum 100 mcg, SPWCV+Alum 600 mcg, SPWCV+Alum 300 mcg
Other · Biological
Lead sponsor
PATH Vaccine Solutions
Other
Eligibility
18 Years to 40 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 5, 2014 · Synced Oct 5, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

NCT02097849
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
dimethyl fumarate, tetanus diphtheria toxoids vaccine, 23-valent pneumococcal polysaccharide vaccine, meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent), non-pegylated interferon
Drug · Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Gilbert, Arizona • Thornton, Colorado • Fort Lauderdale, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 5, 2026, 8:51 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)

NCT03480802
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™, PNEUMOVAX™23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Orlando, Florida • West Palm Beach, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 5, 2026, 8:51 AM EDT
Completed Not applicable Interventional

Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs

NCT00257127
View directory record Official record
Conditions
HIV Infections
Interventions
Pneumococcal 7-valent conjugate vaccine, Pneumococcal polysaccharide vaccine, Hepatitis B vaccine, Measles, mumps, and rubella virus vaccine, live
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 23 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
24
States / cities
Birmingham, Alabama • Alhambra, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 5, 2026, 8:51 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

NCT06824194
View directory record Official record
Conditions
Pneumococcal Immunization
Interventions
PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix
Biological
Lead sponsor
Sanofi
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
103
States / cities
Birmingham, Alabama • Guntersville, Alabama • Oneonta, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 5, 2026, 8:51 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants

NCT04379713
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
1,511 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
41
States / cities
Tucson, Arizona • Fullerton, California • Oxnard, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 5, 2026, 8:51 AM EDT
Completed Phase 2 Interventional

Increasing HAART-Induced Immune Restoration With Cyclosporine

NCT00031070
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine and Zidovudine, Cyclosporine, Hepatitis A Vaccine (Inactivated), Efavirenz, Pneumococcal Conjugate Vaccine, Heptavalent, Rabies Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
15
States / cities
Sacramento, California • Miami, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 5, 2026, 8:51 AM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

NCT00046852
View directory record Official record
Conditions
Infection, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, pneumococcal polyvalent vaccine, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes, carmustine, cyclophosphamide, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 5, 2026, 8:51 AM EDT
Active, not recruiting Not applicable Interventional

Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)

NCT01527591
View directory record Official record
Conditions
Infection in Solid Organ Transplant Recipients
Interventions
Pneumococcal Conjugate Vaccine 13 (PCV13)
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
12 Months to 59 Months
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 5, 2026, 8:51 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age

NCT04642079
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
20vPnC
Biological
Lead sponsor
Pfizer
Industry
Eligibility
15 Months to 17 Years
Enrollment
839 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
43
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Oct 5, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

Prospective Trial of Vaccine Responses in Childhood Cancer Survivors

NCT00505063
View directory record Official record
Conditions
Childhood Cancer, Multiple Diseases
Interventions
Immunization Schedule patients <7 years., Immunization Schedule patients > or = to 7 years and <11 years of age, Immunization Schedule patients > or = to 11 years of age
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
2 Years to 18 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 5, 2026, 8:51 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

NCT00806195
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
MenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus influenza b) Vaccine, IPV (Inactivated Polio Vaccine) Vaccine, Pneumococcal conjugate Vaccine, MMR (Measles, Mumps, and Rubella) Vaccine, Varicella Vaccine, Hepatitis A Virus
Biological
Lead sponsor
Novartis
Industry
Eligibility
55 Days to 89 Days
Enrollment
7,744 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
130
States / cities
Birmingham, Alabama • Dothan, Alabama • Tuscon, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Oct 5, 2026, 8:51 AM EDT
Completed Phase 1 Interventional

Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma

NCT00834665
View directory record Official record
Conditions
Multiple Myeloma
Interventions
hTERT vaccine, GM-CSF, PCV, T cell infusion, GM-CSF, PCV, T cell infusion
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 5, 2026, 8:51 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years

NCT00761631
View directory record Official record
Conditions
Healthy Subjects
Interventions
13 valent pneumococcal conjugate vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
15 Months to 18 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
36
States / cities
Benton, Arkansas • Fayetteville, Arkansas • Jonesboro, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 5, 2026, 8:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

BLYS and IFN in SLE

NCT00611611
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
fluzone, pneumovax
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Oct 5, 2026, 8:51 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Multilevel Intervention of COVID-19 Vaccine Uptake Among Latinos

NCT06156228
View directory record Official record
Conditions
Vaccine Hesitancy
Interventions
Multilevel Intervention
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 5, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

NCT03313037
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Prevnar 13, PPSV23, Saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years to 64 Years
Enrollment
444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
14
States / cities
Anaheim, California • Coral Gables, Florida • DeLand, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 5, 2026, 8:51 AM EDT